Figure 4 | Scientific Reports

Figure 4

From: Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack

Figure 4

Model structure of cost-effectiveness analysis. (A) is the decision tree model within 90 days, and (B) is the long-term Markov model. Locations in the model where prescribers can make a decision (squares), chance nodes that are under the control of transition probabilities (circles), and terminal nodes (triangles) are presented. Transitions to future health states leading from the other health states are the same as for the minor or no disability branch. ECH extracranial hemorrhage, ICH intracerebral hemorrhage, MI myocardial infarction.

Back to article page